nature portfolio

Corresponding author(s):	Florence L. Marlow	
Last updated by author(s):	05/23/2024	
-		

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Sta	atistics		
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed		
x The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
X A statement on whether measurements were taken from distinct samples or whether the same sample was measured repea		nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.		
	X A description of all covariates tested		
	x A descripti	on of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
Х	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.		
x	For Bayesia	an analysis, information on the choice of priors and Markov chain Monte Carlo settings	
x	For hierard	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes	
X	Estimates of	of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated	
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.	
So	ftware and	d code	
Poli	cy information a	about <u>availability of computer code</u>	
Data collection N/A		N/A	
Da	ata analysis	N/A	
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.			
Da	ta		
All	manuscripts mu - Accession codes, - A description of	about <u>availability of data</u> ust include a <u>data availability statement</u> . This statement should provide the following information, where applicable: , unique identifiers, or web links for publicly available datasets any restrictions on data availability sets or third party data, please ensure that the statement adheres to our <u>policy</u>	
	Data availability statements have been included throughout the manuscript		

Research inv	olving hur	man participants, their data, or biological material	
Policy information a and sexual orientati		ith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> hnicity and racism.	
Reporting on sex and gender		N/A	
Reporting on race, ethnicity, or other socially relevant groupings Population characteristics		N/A N/A	
Ethics oversight		N/A	
Note that full information	tion on the appro	oval of the study protocol must also be provided in the manuscript.	
E: 1.1			
Field-spe	cific re	porting	
Please select the on	e below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
x Life sciences	Ве	ehavioural & social sciences	
For a reference copy of the	ne document with a	Il sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
Life scien	ices stu	ıdy design	
All studies must disc	close on these p	points even when the disclosure is negative.	
Data exclusions None Replication included throughout		oughout manuscript files	
		oughout manuscript files	
		pughout manuscript files	
Blinding	included throughout manuscript files		
Behaviou	iral & s	ocial sciences study design	
All studies must disc	close on these p	points even when the disclosure is negative.	
Study description N/			
Research sample	N/A	Α	
		A	

Research sample N/A

Sampling strategy N/A

Data collection N/A

Timing N/A

Data exclusions N/A

Non-participation N/A

Randomization N/A

All studies must disclose on	these points even when the disclosure is negative.
Study description	N/A
Research sample	N/A
Sampling strategy	N/A
Data collection	N/A
Timing and spatial scale	N/A
Data exclusions	N/A
Reproducibility	N/A
Randomization	N/A
Blinding	N/A
Field conditions Location	ion and transport
Access & import/export	
Disturbance	
Reporting fo	r specific materials, systems and methods uthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, yant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

All antibodies are described

Validation is described

Antibodies used

Validation

Eukaryotic cell line	28
Policy information about <u>cel</u>	l lines and Sex and Gender in Research
Cell line source(s)	N/A
Authentication	N/A
Mycoplasma contamination	on N/A
Commonly misidentified li (See <u>ICLAC</u> register)	nes N/A
Palaeontology and	d Archaeology
Specimen provenance	N/A
Specimen deposition	N/A
Dating methods	N/A
Tick this box to confirm	n that the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	N/A
Note that full information on th	e approval of the study protocol must also be provided in the manuscript.
	research organisms dies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in
Laboratory animals	Danio rerio (zebrafish) lab raised strains
Wild animals	N/A
Reporting on sex	Yes, the study is on sex determination
Field-collected samples	N/A
Ethics oversight	IACUC details provided
Note that full information on th	e approval of the study protocol must also be provided in the manuscript.
Clinical data	
Policy information about <u>clir</u> All manuscripts should comply v	nical studies with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	N/A
Study protocol	N/A
Data collection	N/A
Outcomes	N/A

Dual use research of concern

Policy information about <u>dual use research of concern</u>

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No Yes X Public health X National security X Crops and/or livest X Ecosystems X Any other significan	
Experiments of concer	n
Does the work involve an	y of these experiments of concern:
No Yes Demonstrate how to render a vaccine ineffective Confer resistance to therapeutically useful antibiotics or antiviral agents Enhance the virulence of a pathogen or render a nonpathogen virulent Increase transmissibility of a pathogen Alter the host range of a pathogen Enable evasion of diagnostic/detection modalities Enable the weaponization of a biological agent or toxin Any other potentially harmful combination of experiments and agents	
Plants	
Seed stocks	N/A
Novel plant genotypes	N/A
Authentication	N/A
ChIP-seq	
Data deposition Confirm that both raw and final processed data have been deposited in a public database such as GEO. Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks. Data access links May remain private before publication.	
Files in database submission	
Genome browser session (e.g. UCSC)	
Methodology	
Replicates	
Sequencing depth	
Antibodies	
Peak calling parameters	

Data quality

Flow Cytometry		
Plots Confirm that: The axis labels state the market The axis scales are clearly visib All plots are contour plots with		
	of cells or percentage (with statistics) is provided.	
Methodology Sample preparation		
Instrument		
Software		
Cell population abundance		
Gating strategy		
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.		
	o	
Magnetic resonance im	aging	
Experimental design		
Design type		
Design specifications		
Behavioral performance measures		
Imaging type(s)		
Field strength		
Sequence & imaging parameters		
Area of acquisition		
Diffusion MRI Used	☐ Not used	
Preprocessing		
Preprocessing software		
Normalization		
Normalization template		
Noise and artifact removal		
Volume censoring		
Statistical modeling & inferer	ce	
Model type and settings		
Effect(s) tested		

Software

nature portfolio
reporting su
summary

\rightarrow	
ଽ	
ч	
s	
Ņ	
	۱

Specify type of analysis:		
Statistic type for inference		
(See Eklund et al. 2016)		
Correction		
Models & analysis		
n/a Involved in the study		
Functional and/or effective connectivity		
Graph analysis		
Multivariate modeling or predictive analysis		
Functional and/or effective connectivity		
Graph analysis		
Multivariate modeling and predictive analysis		